... and the use of financial arrangements for new oncology and non-oncology drugs?
Read moreThe UK will continue to adopt decisions taken by the European Commission on the approval of new mark...
Read moreWhen critically appraising a clinical study, it is key to firstly identify the sources of uncertaint...
Read moreTo facilitate biosimilar uptake, several mechanisms encouraging biosimilar uptake have been implemen...
Read moreA survey of employees within pricing and market access n pharma and biotech companies.
Read moreRemap Consulting are ideally placed to support the completion of price certificates ready for legali...
Read moreGVD is a core document, which may be considered the “heart” of the pharmaceutical product’s pa...
Read moreThis newsletter will discuss the early access processes operating within the UK and discuss the adva...
Read moreA multidisciplinary process that uses explicit methods to determine the value of a health technology...
Read moreHow has the data available within NCRAS been utilized within the CDF overseen by NICE, in partnershi...
Read more